Intellia Therapeutics, a Novartis ($NVS)-backed biotech working on gene-editing technology, leased a sizable research space in the hotbed of Cambridge, MA. As the Boston Business Journal reports, the company is taking up 65,000 square feet in a building that formerly hosted Vertex Pharmaceuticals ($VRTX). Intellia is working off of a $70 million funding round closed last year, using CRISPR technology to edit genetic code in hopes of crafting therapies for cancer and autoimmune disease. More